Skip to content
Sign in

TMDX · NASDAQ

TransMedics Group (TMDX) Stock Price & Fundamentals

$481.14−0.80%−$3.88End-of-day price as of Oct 9, 2026

TransMedics Group (TMDX) closed at $481.14 on Oct 9, 2026, down 0.80% from the previous close of $485.02.

Share price, past year

1Y −12.98%

52-week range $455.15 – $557.11. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$481.14
Sep 30, 2026$496.08
Aug 31, 2026$495.15
Jul 31, 2026$472.50
Jun 30, 2026$462.65
May 29, 2026$468.42
Apr 30, 2026$488.36
Mar 31, 2026$490.19
Feb 27, 2026$500.29
Jan 30, 2026$502.98
Dec 31, 2025$509.05
Nov 28, 2025$539.07
Oct 31, 2025$539.00

Key statistics

Market cap
$16.66B
P/E (TTM)
124.7
EPS (TTM)
$3.86
Revenue (TTM)
$668.47M
Net income (TTM)
$151.70M
Shares outstanding
34.6M
Dividend yield
—
52-week range
$455.15 – $557.11

TransMedics Group's market cap is $16.66B, based on a share price of $481.14 and 34.6M shares outstanding as of Jun 30, 2026.

Financials

TransMedics Group reported revenue of $605.49M for fiscal 2025, up 37.13% from fiscal 2024.

TransMedics Group earned net income of $190.29M in fiscal 2025, a net margin of 31.4%.

Fiscal 2025 revenue was the highest in the 8 years shown.

Annual revenue

FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
TransMedics Group annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$605.49M+37.1%$190.29M31.4%$4.87$133.59M
FY2024ended Dec 31, 2024$441.54M+82.7%$35.46M8.0%$1.01−$80.94M
FY2023ended Dec 31, 2023$241.62M+158.5%−$25.03M−10.4%−$0.77−$164.88M
FY2022ended Dec 31, 2022$93.46M+208.8%−$36.23M−38.8%−$1.23−$57.72M
FY2021ended Dec 31, 2021$30.26M+18.0%−$44.22M−146.1%−$1.60−$32.38M
FY2020ended Dec 31, 2020$25.64M+8.6%−$28.75M−112.1%−$1.16−$30.72M
FY2019ended Dec 28, 2019$23.60M+81.3%−$33.55M−142.1%−$2.36−$32.45M
FY2018ended Dec 29, 2018$13.02M—−$23.76M−182.5%−$17.48−$26.40M
TransMedics Group quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$189.95M$14.68M$0.41
Q1 FY2026ended Mar 31, 2026$173.93M$7.32M$0.20
Q4 FY2025ended Dec 31, 2025$160.76M$105.38M$2.59
Q3 FY2025ended Sep 30, 2025$143.82M$24.32M$0.66
Q2 FY2025ended Jun 30, 2025$157.37M$34.91M$0.92
Q1 FY2025ended Mar 31, 2025$143.54M$25.68M$0.70
Q4 FY2024ended Dec 31, 2024$121.62M$6.86M$0.19
Q3 FY2024ended Sep 30, 2024$108.76M$4.22M$0.12

Company profile

Name
TransMedics Group, Inc.
Ticker
TMDX
Exchange
NASDAQ
Industry (SEC SIC)
Electromedical & Electrotherapeutic Apparatus
Headquarters
200 Minuteman Road, Andover, MA 01810
Incorporated in
MA
Fiscal year ends
December
SEC CIK
0001756262

Recent SEC filings

Frequently asked questions

What is TransMedics Group's stock price?

TransMedics Group (TMDX) closed at $481.14 on Oct 9, 2026, down 0.80% from the previous close of $485.02.

What is TransMedics Group's market cap?

TransMedics Group's market cap is $16.66B, based on a share price of $481.14 and 34.6M shares outstanding as of Jun 30, 2026.

How much revenue does TransMedics Group make?

TransMedics Group reported revenue of $605.49M for fiscal 2025, up 37.13% from fiscal 2024.

What is TMDX's P/E ratio?

TransMedics Group's price-to-earnings ratio is 124.7, based on trailing twelve-month diluted EPS of $3.86.

Does TransMedics Group pay a dividend?

Yes. TransMedics Group declared $0.00 per share in dividends for fiscal 2025.

Sources and methodology

Fundamentals come from TransMedics Group, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures